Background Several studies have indicated that CYP2C19 loss-of-function polymorphisms have a higher risk of stent thrombosis (ST) after percutaneous coronary interventions (PCIs). However, this association has not been investigated thoroughly in a Chinese population. In this study, we aimed to determine the effect of CYP2C19*2 and CYP2C19*3 loss-of-function polymorphisms on the occurrence of ST and other adverse clinical events in a Chinese population. Methods We designed a cohort study among 1068 consecutive patients undergoing intracoronary stent implantation after preloading with 600 mg of clopidogrel. CYP2C19*2 and CYP2C19*3 were genotyped by using polymerase chain reaction-restriction fragment length polymorphism analysis. The adverse clinical events recorded were ST, death, myocardial infarction (MI), and bleeding events. The primary end point of the study was the incidence of cumulative ST within 1 year after PCI. The secondary end point was other adverse clinical outcomes 1 year after the procedure. Results The cumulative 1-year incidence of ST was 0.88% in patients with extensive metabolizers (EMs) (CYP2C19*1/*1 genotype), 4.67% in patients with intermediate metabolizers (IMs) (CYP2C19*1/*2 or *1/*3 genotype), and 10.0% in patients with poor metabolizers (PMs) (CYP2C19*2/*2, *2/*3, or *3/*3 genotype) (P<0.001). The one-year event-free survival was 97.8% in patients with EMs, 96.5% in patients with IMs, and 92.0% in patients with PMs (P = 0.014). Multivariate analysis confirmed the independent association of CYP2C19 loss-of-function allele carriage with ST (P = 0.009) and total mortality (P<0.05). Conclusion PM patients had an increased risk of ST, death, and MI after coronary stent placement in a Chinese population.
References
[1]
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, et al. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502.
[2]
Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, et al. (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84: 891–896.
[3]
Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, et al. (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30: 916–22.
[4]
Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, et al. (2010) CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 31: 3046–53.
[5]
Yang YN, Wang XL, Ma YT, Xie X, Fu ZY, et al. (2010) Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost. 2010 16: 579–83.
[6]
Fuchshuber-Moraes M, Carvalho RS, Rimmbach C, Rosskopf D, Carvalho MA, et al. (2011) Aminoglycoside-induced suppression of CYP2C19*3 premature stop codon. Pharmacogenet Genomics 21: 694–700.
[7]
Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP (2011) CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011 306: 2704–14.
[8]
Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, et al. (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53: 849–856.
[9]
Xie X, Ma YT, Yang YN, Li XM, Liu F, et al. (2010) Alcohol consumption and ankle-to-brachial index: results from the Cardiovascular Risk Survey. PLoS One 5(12): e15181.
[10]
American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32 Suppl 1S62–67.
[11]
Xie X, Ma YT, Yang YN, Fu ZY, Li XM, et al. (2010) Polymorphisms in the SAA1/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the Cardiovascular Risk Survey. PLoS One 5: e13997.
[12]
Xie X, Ma YT, Yang YN, Fu ZY, Li XM, et al. (2011) Polymorphisms in the SAA1 gene are associated with ankle-to-brachial index in Han Chinese healthy subjects. Blood Press 20: 232–238.
[13]
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, et al. (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354–62.
[14]
Caraco Y (2004) Genes and the response to drugs.N Engl J Med. 351: 2867–9.
[15]
Shi WX, Chen SQ (2004) Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol 10: 1961–1963.
[16]
Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309–17.
[17]
Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302: 849–57.
[18]
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, et al. (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115: 2344–2351.
[19]
Thygesen K, Alpert JS, White HD (2007) Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction.Universal definition of myocardial infarction. Eur Heart J 28: 2525–38.
[20]
Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, et al. (2012) Validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125(11): 1424–31.
[21]
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, et al. (2010) Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363(18): 1704–14.
[22]
Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41: 913–58.
[23]
Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, et al. (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5: 2429–2436.
[24]
Umemura K, Furuta T, Kondo K (2008) The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 6: 1439–1441.
[25]
Hulot JS, Bura A, Villard E, Azizi M, Remones V, et al. (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244–2247.
[26]
Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, et al. (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4, IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high risk vascular patients. Pharmacogenet Genomics 17: 1057–1064.
[27]
Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, et al. (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51: 1925–1934.
[28]
Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, et al. (2008) Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 101: 1088–1093.
[29]
Tang XF, He C, Yuan JQ, Meng XM, Yang YJ, et al. (2011) Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi. 2011 39: 617–20.
[30]
Luo Y, Zhao YT, Verdo A, Qi WG, Zhang DF, et al. (2011) Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. J Int Med Res 39: 2012–9.
[31]
Chen M, Liu XJ, Yan SD, Peng Y, Chai H, et al. (2012) Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease. Atherosclerosis. 220(1): 168–71.
[32]
Oh IY, Park KW, Kang SH, Park JJ, Na SH, et al. (2012) Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart. 98(2): 139–44.
[33]
Galiavich AS, Valeeva DD, Minnetdinov RSh, Arkhipova AA, Akhmetov II, et al. (2012) CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel. Kardiologiia. 52(4): 20–4.
[34]
Tazaki J, Jinnai T, Tada T, Kato Y, Makiyama T, et al. (2012) Prediction of clopidogrel low responders by a rapid CYP2C19 activity test. J Atheroscler Thromb. 19(2): 186–93.
[35]
Tello-Montoliu A, Jover E, Marín F, Bernal A, Lozano ML, et al. (2012) Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol (Engl Ed). 2012 65(3): 219–26.
Van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, et al. (2009) Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 53: 1399–1409.
[38]
Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, et al. (2009) Acute ST-Elevation and Non–ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363–375.
[39]
Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, et al. (2011) Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343: d4588.
